A Study of ABT-751 in Patients With Colorectal Cancer

Phase 2

Completed

• Conditions: Colorectal Cancer

• Registration Number: NCT00073138
• Lead Sponsor: Abbott

Brief Summary

The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with colorectal cancer. Patients will receive ABT-751 by mouth daily for 21 days. Patients will be off drug for 7 days before starting the next cycle of drug.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-08
• Study First Submitted: 2003-11-17
• Study First Submitted QC: 2003-11-17
• Study First Posted: 2003-11-18
• Study Completion: 2005-02
• Status Verified: 2007-11
• Last Update Submitted: 2007-11-28
• Last Update Posted: 2007-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Objective Response Rate in subjects with Recurrent Colorectal Cancer	1 year

Secondary Outcome Measures

Name	Time	Method
Time to Tumor Progression (TTP)	1 year
Survival	2 years
Toxicities associated with treatment administration	1 year

Trial Locations

Locations (6)

University of Chicago Medical Center; 🇺🇸 Chicago, Illinois, United States

University of Wisconsin Medical Center; 🇺🇸 Madison, Wisconsin, United States

University of Southern California; 🇺🇸 Los Angeles, California, United States

Cancer Institute Medical Group; 🇺🇸 Santa Monica, California, United States

Northwestern University; 🇺🇸 Chicago, Illinois, United States

Duke University Medical Center; 🇺🇸 Durham, North Carolina, United States